Predictive Significance of Circulating Histones in Hepatocellular Carcinoma Patients Treated with Sorafenib
Authors:
- Francesca SalaniFSFrancesca Salani
- Maryam LataraniMLMaryam Latarani
- Andrea Casadei-GardiniACAndrea Casadei-Gardini
- Lorenzo FornaroLFLorenzo Fornaro
- Caterina VivaldiCVCaterina Vivaldi
- Irene PecoraIPIrene Pecora
- Giorgia MarisiGiorgia Marisi
- Matteo CanaleMCMatteo Canale
- Paola UliviPaola Ulivi
- Mario ScartozziMario Scartozzi
Open Access
- 27 April 2022
- journal article
- research article
- Published by Taylor & Francis in Epigenomics
- Vol. 14 (9) , 507-517
Abstract
Background: Predictive biomarkers for advanced hepatocellular carcinoma are lacking. EZH2 drives sorafenib resistance through H3K27me3 and is counteracted by SETD2, which catalyzes H3K36me3. The au... Plain language summary Hepatocellular carcinoma (HCC) is responsible for approximately 10% of all cancer-related deaths worldwide. It is caused mainly by dysmetabolic syndrome, which is the presenc...Keywords
Funding Information
- Higher Education Innovation Fund grant for industrial collaboration (20,000 Euros)
- University of Pisa (10,000 Euros)
This publication has 33 references indexed in Scilit:
- Histone Modifications and CancerCold Spring Harbor Perspectives in Biology, 2016
- Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenibTherapeutic Advances in Gastroenterology, 2015
- Circulating nucleosomes as epigenetic biomarkers in pancreatic cancerClinical Epigenetics, 2015
- LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2Oncotarget, 2015
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenibJournal of Hepatology, 2014
- Histone Modifications, Stem Cells and Prostate CancerCurrent Pharmaceutical Design, 2014
- The ConsensusPathDB interaction database: 2013 updateNucleic Acids Research, 2012
- H3K36 Methylation Antagonizes PRC2-mediated H3K27 MethylationJournal of Biological Chemistry, 2011
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Assessment of the prognosis of cirrhosis: Child–Pugh versus MELDJournal of Hepatology, 2005